HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, œthe Company), announced today that the Company intends to voluntarily terminate the listing of its common stock on the...
The vultures are circling Aravive. Still reeling from a phase 3 flop, the cash-strapped biotech has “several weeks” to find a partner or funding—and is laying off 70% of its staff to preserve the little money it has left.
Aravive’s phase 3 ovarian cancer trial has bombed, taking another chunk out of its share price. And, with cash down to $18 million at the end of the second quarter, the biotech has a matter of months to find a way out of its predicament.
Trial did not meet primary endpoint of progression-free survivalCash at the end of Q2 of approximately $18M (unaudited) is expected to be sufficient to fund operations into early Q4 2023 HOUSTON,...
HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, œthe Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today...
HOUSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, the Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
HOUSTON, June 05, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, œthe Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today...
HOUSTON, May 25, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, œthe Company), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today...
Trial initiation anticipated in 2H 2023 with topline data anticipated in 2H 2025Updated Phase 1b/2 ccRCC data to be presented at ASCO 2023 HOUSTON, May 16, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc....